Myokardia Inc(NASDAQ:MYOK) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $3.55M. Analysts estimated a revenue of $4.83M. Earnings per share were $-0.37. Analysts had estimated an EPS of $-0.33.
In a different note, BMO Capital said it Initiates Coverage on Myokardia Inc, according to a research note issued on Jul 20, 2016. The shares have been rated ‘Outperform’ by the firm.
Several Insider Transactions has been reported to the SEC. On May 6, 2016, Anastasios Gianakakos (CEO) purchased 2,279 shares at $8.50 per share price.Also, On Nov 5, 2015, Jonathan C Fox (Chief Medical Officer) purchased 3,000 shares at $10.00 per share price.On Nov 5, 2015, Mark L Perry (director) purchased 5,000 shares at $10.00 per share price, according to the Form-4 filing with the securities and exchange commission.
MyoKardia Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). In addition the Company is evaluating MYK-461 and initiated a Phase I clinical program for the treatment of HCM.